AI Article Synopsis
- The study explores how dynamic functionalization and molecular recognition on biological membranes influence physiological processes.
- The researchers developed a glycocalyx model using glycosylation of liposomes that can be reversed and covalently bonded, allowing for specific recognition by the lectin concanavalin A.
- This approach demonstrates a novel method for liposome glycosylation that enables liposome agglutination and is a first-of-its-kind in scientific research.
Article Abstract
The interplay of dynamic functionalization and specific molecular recognition on biological membranes is key to numerous physiological processes. In this work we present a simple glycocalyx model based on the covalent yet reversible glycosylation of liposomes and subsequent recognition by a lectin. Reversible thioester exchange of membrane embedded amphiphilic thioesters with thiol-tagged d-mannose in solution is performed at physiologically relevant conditions. Recognition with the lectin concanavalin A is possible directly from this reaction mixture, leading to liposome agglutination. To the best of our knowledge, the dynamic covalent glycosylation of liposomes is so far unprecedented.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c7ob00805h | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells.
J Clin Invest
November 2024
Department of Digestive Diseases and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Liposomal drug delivery systems have revolutionized traditional cytotoxic drugs. However, the relative instability and toxicity of the existing liposomal drug delivery systems compromised their efficacy. Herein, we present Rg3-lipo, an innovative drug delivery system using a glycosyl moiety-enriched ginsenoside (Rg3).
View Article and Find Full Text PDFIn vitro treatment with liposome-encapsulated Mannose-1-phosphate restores N-glycosylation in PMM2-CDG patient-derived fibroblasts.
Mol Genet Metab
October 2024
Glycomine Inc., San Carlos, CA, USA. Electronic address:
PMM2-CDG is the most common congenital disorder of glycosylation (CDG). Patients with this disease often carry compound heterozygous mutations of the gene encoding the phosphomannomutase 2 (PMM2) enzyme. PMM2 converts mannose-6-phosphate (M6P) to mannose-1-phosphate (M1P), which is a critical upstream metabolite for proper protein N-glycosylation.
View Article and Find Full Text PDFThe glycosylation deficiency of flavivirus NS1 attenuates virus replication through interfering with the formation of viral replication compartments.
J Biomed Sci
June 2024
State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; and School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China.
Article Synopsis
- Flavivirus replication relies on the NS1 protein, which remodels the endoplasmic reticulum (ER) to form replication compartments necessary for the virus.
- The study shows that the glycosylation of NS1 is crucial for its role in ER remodeling and that mutations or treatments affecting this process can hinder viral replication.
- Understanding the importance of NS1 glycosylation opens up potential new strategies for fighting flavivirus infections.
Novel therapeutic perspectives for wet age-related macular degeneration: RGD-modified liposomes loaded with 2-deoxy-D-glucose as a promising nanomedicine.
Biomed Pharmacother
June 2024
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, PR China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, PR China. Electronic address:
Choroidal neovascularization (CNV), characterized as a prominent feature of wet age-related macular degeneration (AMD), is a primary contributor to visual impairment and severe vision loss globally, while the prevailing treatments are often unsatisfactory. The development of conventional treatment strategies has largely been based on the understanding that the angiogenic switch of endothelial cells is dictated by angiogenic growth factors alone. Even though treatments targeting vascular endothelial growth factor (VEGF), like Ranibizumab, are widely administered, more than half of the patients still exhibit inadequate or null responses, emphasizing the imperative need for solutions to this problem.
View Article and Find Full Text PDFLiposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.
Mol Genet Metab
June 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA; Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA; Department of Biophysics, University of Pécs Medical School, 7624 Pécs, Hungary. Electronic address:
Phosphomannomutase 2 (PMM2) converts mannose-6-phospahate to mannose-1-phosphate; the substrate for GDP-mannose, a building block of the glycosylation biosynthetic pathway. Pathogenic variants in the PMM2 gene have been shown to be associated with protein hypoglycosylation causing PMM2-congenital disorder of glycosylation (PMM2-CDG). While mannose supplementation improves glycosylation in vitro, but not in vivo, we hypothesized that liposomal delivery of mannose-1-phosphate could increase the stability and delivery of the activated sugar to enter the targeted compartments of cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!